Our science is visionary.
Our commitment is relentless.
preserve vision and
prevent blindness.
About Us
Qlaris Bio is a clinical stage biotechnology company founded on a relentless commitment to develop innovative first-in-class therapies that can make a truly impactful change for patients suffering from serious and debilitating ophthalmic diseases.
Our Approach
We are exploring novel mechanisms of action to address the largest unmet needs in ophthalmology.
Our Science
Our lead asset, QLS-111, has a unique vasodilatory mechanism of action and is designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) and distal outflow resistance beyond the trabecular meshwork. By reducing EVP, and distal outflow resistance, QLS-111 has the potential to enable the achievement of lower IOP targets than available therapies currently allow.
QLS-111 is currently in development for the treatment of Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome.
Recent News See All News
Qlaris Bio’s Novel IOP-Lowering Product, QLS-111, Is Dosed In Phase II Trials
newsApril 2, 2024
A first-in-class product, QLS‑111 is designed to lower intraocular pressure (IOP) beyond currently achievable levels in patients with glaucoma by targeting episcleral venous pressure (EVP) DEDHAM, Mass. — April 2, 2024 — Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate […]
An Interview With Dr. Shan Lin – Unmet Needs in Glaucoma & New Treatments On The Horizon
newsApril 2, 2024
Please click below for an interview with Dr. Shan Lin, co-research director of the Glaucoma Center of San Francisco and a member of the Scientific Advisory Board of Qlaris Bio – Interviewed by Carey Powers of Powers & Company at the Glaucoma 360 New Horizons Forum 2024. https://vimeo.com/929695079